Related Experiment Videos
Southwest Oncology Group studies in hormone-refractory prostate cancer
M H Hussain1, B Blumenstein, M Eisenberger
1Division of Hematology/Oncology, Veterans Administration Medical Center, Wayne State University, Detroit, MI, USA.
Abstract:
Virtually all patients with hormone-refractory prostate cancer will eventually succumb to their diseases with no demonstrable increase in survival with any second-line therapy, thus making the conventional approach to the treatment of this disease palliative. The Southwest Oncology Group (SWOG) Genitourinary Committee strategy in investigating therapy for hormone-refractory prostate cancer is focused on the application of biologically guided treatments targeting primary patients with limited prior hormonal therapy, taking into account evolving concepts regarding the definitions of "hormone-refractory" disease and response criteria. This report reviews data from selected SWOG studies conducted in the past 10 years, and outlines the rationale and design of current and future studies conducted by the Genitourinary Committee of the SWOG in hormone-refractory prostate cancer.
Insights
For hormone-refractory prostate cancer, current second-line therapies offer palliative care. The Southwest Oncology Group (SWOG) is developing targeted, biologically guided treatments for earlier stages of this disease.
Area of Science:
- Oncology
- Urology
Background:
- Hormone-refractory prostate cancer (HRPC) presents a significant challenge, with limited survival benefits from current second-line therapies, necessitating palliative care.
- The definition of HRPC and response criteria are evolving, impacting treatment strategies.
Purpose of the Study:
- To review data from Southwest Oncology Group (SWOG) studies over the past decade investigating HRPC therapies.
- To outline the rationale and design of ongoing and future SWOG Genitourinary Committee studies in HRPC.
Main Methods:
- Review of selected SWOG clinical trial data from the last 10 years.
- Analysis of treatment strategies focusing on biologically guided therapies for HRPC.
Main Results:
- Current second-line therapies for HRPC demonstrate limited efficacy, with outcomes remaining largely palliative.
- SWOG's strategy emphasizes biologically guided treatments for patients with limited prior hormonal therapy.
Conclusions:
- There is a critical need for novel therapeutic approaches in hormone-refractory prostate cancer.
- SWOG is actively pursuing targeted treatment strategies for HRPC, focusing on evolving disease definitions and patient stratification.